Vaxzevria receives full Marketing Authorisation in the EU for the prevention of COVID-19
Full Marketing Authorisation based on totality of efficacy and safety data confirming the benefits of Vaxzevria.AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted full Marketing Authorisation (MA) in the European Union (EU). Vaxzevria was originally granted a conditional Marketing Authorisation (cMA) due to the urgency of the COVID-19 pandemic. As there continues to be sufficient evidence of safety and efficacy confirming the benefits of Vaxzevria, the European Medicines Agency (EMA) has now granted a full MA. This decision follows positive